Mythic Therapeutics


Mythic Therapeutics’ innovative FateControl technology expands the potential of Antibody Drug Conjugates (ADCs) to destroy cancer and avoid normal cells.

Employees

11-50

Links


Org chart

Sandra Poole
Chief Operating Officer
Collapse
Ting-Hui Wu
Vice President, Clinical Development
Paul Basciano
Senior Vice President, Product Team Leader
Ben Hutchins
Vice President Technical Operations

Board & advisors

Peter Hecht
Director
Richard Gregory
Scientific Advisor
Douglas Williams
Scientific Advisor
Michael Vasconcelles
Scientific Advisor
John Lambert
Scientific Advisor
Scott Dylla
Scientific Advisor